

Financial Results for the First Half of 2025 – Steady Growth Momentum

Peania, September 18, 2025 – Lavipharm Group reports an increase in its consolidated sales during the First Half of 2025.

Specifically, consolidated sales from continuing operations amounted to €31.0 million, compared to €29.3 million in the corresponding period of 2024, recording an increase of 5.7%. Consolidated Sales, after deduction of rebates and clawback, amounted to €26.7 million, compared to €25.0 million in the corresponding period of 2024, reflecting an increase of 6.8%. Adjusted EBITDA stood at €7.7 million, versus €5.9 million in the First Half of 2024, marking a 29.4% increase. Consolidated EBITDA for the period includes the profit from the sale of subsidiary Pharma Plus. This profit, amounting to €973 thousand, is presented in the Group's financial statements as a result of discontinued operations. The accounting impact of the valuation of the stock option and stock award plans amounted to €480 thousand, compared to €675 thousand in the corresponding period of 2024. It should be noted that the obligations arising from the implementation of these programs affect EBITDA, according to IFRS, but do not require any cash outflow.

Gross profit stood at €12.4 million, versus €12.7 million in 2024.

Consolidated net profit after tax amounted to €2.6 million, compared to €7.7 million in the First Half of 2024. This decrease is attributed to the recognition of a deferred tax asset of €5.7 million in the First Half of 2024, stemming from the Group's decision to liquidate subsidiaries with accumulated past losses. Excluding this extraordinary income from the First Half of 2024, consolidated net profit after tax would have amounted to €2.0 million, indicating a 32% increase in net profitability for the period.

The Group's net debt as of 30/06/2025 amounted to €27.5 million.

*"The results we announce today continue our growth trajectory of the past years. Although our sales in the First Half show moderate growth, we are striving and working towards a very strong Second Half. Based on the orders already received from abroad, our international sales are expected to record a significant increase compared to the First Half of the year. In addition, during the Second Half, we anticipate substantial growth in the pharmaceutical cannabis sector, where the market is expanding rapidly," stated **Mr. Vassilis Baloumis, Chief Financial Officer of Lavipharm**. "Our investments are gradually revealing their full potential. Our steady upward path is a source of strong commitment to innovation and quality, while we remain dedicated to our Vision. We continue to focus on sectors with significant growth prospects, which will contribute to achieving our long-term objectives and strengthening our position in the market".*

###

For further information:

Investor Relations

Vassilis Baloumis

Tel.: +30 210 6691 121

ir@lavipharm.com

Corporate Communications

Vivien Thomas

Tel.: +30 210 6691 404
vthomas@lavipharm.com